ライフサイエンスコーパス: N-acetyllactosamine

1 s with increased branching and extended poly-N-acetyllactosamine.

2 not require DD-heptose to form the terminal N-acetyllactosamine.

3 opically labeled CMP-N-acetylneuraminate and N-acetyllactosamine.

4 ic pathway leading to the addition of sialyl-N-acetyllactosamine.

5 ipooligosaccharide (LOS) which terminates in N-acetyllactosamine.

6 ently add N-acetyllactosamine to linear poly-N-acetyllactosamines.

7 -3GalNAc termini, and some increases in poly-N-acetyllactosamines.

8 ding a galactose to linear and branched poly-N-acetyllactosamines.

9 ther beta-Xyl or chains of, on average, five N-acetyllactosamine (-3Galbeta1-4GlcNAcbeta1-) (LacNAc)

10 ntain primarily complex-type structures with N-acetyllactosamine, a preferred galectin ligand.

11 s for lactose, lactulose, lacto-N-biose, and N-acetyllactosamine, all of which exhibit binding enthal

12 methyl beta-galactopyranoside, lactose, and N-acetyllactosamine and a greater -delta H value for the

13 three other H. ducreyi strains also contain N-acetyllactosamine and are highly sialylated (approxima

14 h sequence and linkage data are obtained for N-acetyllactosamine and sialyl-N-acetyllactosamine oligo

15 0 have been previously found to terminate in N-acetyllactosamine and sialyl-N-acetyllactosamine, Neu5

16 ated that itraconazole globally reduced poly-N-acetyllactosamine and tetra-antennary complex N-glycan

17 eyi contain terminal sialic acid attached to N-acetyllactosamine and that this modification is likely

18 rabinose, 2'-O-methyllactose, lacto-N-biose, N-acetyllactosamine, and thiodigalactopyranoside.

19 cans, fetuin N-glycans, synthetic sialylated N-acetyllactosamines, and on alpha(2)-HS-glycoprotein.

20 Complex glycan structural features, such as N-acetyllactosamine antenane, neuraminic acids, and nonr

21 Poly-N-acetyllactosamines are attached to N-glycans, O-glycan

22 ases, which play important roles in how poly-N-acetyllactosamines are synthesized in different accept

23 beled UMP-NeuAc's as the donor substrate and N-acetyllactosamine as the acceptor.

24 at 297.8 K to 6.54 +/- 0.97 x 10(4) M-1 for N-acetyllactosamine at 281.3 K.

25 blood group H on a 6-linked branch of a poly-N-acetyllactosamine backbone.

26 e of galectin-3 (GaL3), a multicompartmented N-acetyllactosamine-binding chimeric lectin, on atheroge

27 that 4-F-GlcNAc (putative inhibitor of poly-N-acetyllactosamine biosynthesis) was more potent than B

28 amine (4-F-GlcNAc), a metabolic inhibitor of N-acetyllactosamine biosynthesis, and analyzed tumor gro

29 osamine is a unique carbohydrate composed of N-acetyllactosamine branches attached to linear poly-N-a

30 N-Acetyllactosamine, but not sucrose, treatment of cells

31 I-branched poly-N-acetyllactosamine can carry bivalent functional oligos

32 lts also showed that monosialyl and disialyl N-acetyllactosamines can serve equally as an acceptor, s

33 s with IGHV4-34*01 heavy chains bind to poly-N-acetyllactosamine carbohydrates (I/i antigen) on eryth

34 syl core may carry predominantly linear poly-N-acetyllactosamine chains, whereas the Manalpha1-3 arm

35 -3 arm may carry predominantly branched poly-N-acetyllactosamine chains.

36 NAc preferentially to galactosyl residues of N-acetyllactosamine close to nonreducing terminals.

37 y crystallographic structure of the galectin-N-acetyllactosamine complex determined by Liao et al.

38 Both glycoproteins display poly-N-acetyllactosamines, consistent with virion assembly in

39 of sialylated glycoforms but a reduction in N-acetyllactosamine containing glycoforms.

40 lyltransferases, SiaA, and LsgB, that affect N-acetyllactosamine containing glycoforms.

41 se-linked glycan structures, including sulfo-N-acetyllactosamine containing modifications.

42 Characterization of the large poly-N-acetyllactosamine containing N-glycans of the TbGnTII

43 TbGT8 influences the processing of the poly N-acetyllactosamine-containing asparagine-linked glycans

44 cterized to demonstrate that they produced a N-acetyllactosamine-containing LOS by silver-stained sod

45 tants that were unable to add sialic acid to N-acetyllactosamine-containing LOS.

46 ans, including some exceptionally large poly-N-acetyllactosamine-containing structures.

47 side GD1a and oligosaccharides containing an N-acetyllactosamine core.

48 A range of N-acetyllactosamine derivatives (compounds 4-7) that hav

49 of CD45, and more specifically, an N-linked N-acetyllactosamine determinant preferentially expressed

50 ate carbohydrate chains consist of repeating N-acetyllactosamine disaccharides with sulfation on the

51 cells, indicating direct inhibition on poly-N-acetyllactosamine elongation and selectin-binding dete

52 complete loss of sialylation of the terminal N-acetyllactosamine epitope and expression of the higher

53 had no effect on sialylation of the terminal N-acetyllactosamine epitope.

54 ncement of both beta(1,6) branching and poly-N-acetyllactosamine expression on N-cadherin.

55 N-acetyllactosamine synthesis, allowing poly-N-acetyllactosamine extension mostly along the linear po

56 Poly-N-acetyllactosamine extension of core 4 branches is, how

57 In O-glycan biosynthesis, N-acetyllactosamine extension of core 4 branches was fou

58 jor product was the oligosaccharide with one N-acetyllactosamine extension on the linear Galbeta1-->4

59 ct contained galactosylated I-branch without N-acetyllactosamine extension.

60 opy compensation, and, with the exception of N-acetyllactosamine, follow a van't Hoff dependence of t

61 ed by the addition of beta1,3-linked GlcA to N-acetyllactosamine followed by sulfation of the C-3 pos

62 branched acceptor than the summation of poly-N-acetyllactosamines formed individually on each unbranc

63 group consists of Neu5Acalpha2-3(lactose or N-acetyllactosamine) forms that lack the branched mannos

64 -sialyltransferases for the common substrate N-acetyllactosamine (Gal(beta)1-4GlcNAc-R) on N-linked c

65 timal configuration of sulfate esters on the N-acetyllactosamine (Galbeta1-->4GlcNAc) core of sulfosi

66 hyroid where the presence of 3'-sulfation of N-acetyllactosamine has been reported.

67 possess essentially the same affinities for N-acetyllactosamine; however, the animal lectin shows a

68 ialylated, triantennary oligosaccharide with N-acetyllactosamine (i.e. Galbeta1,4GlcNAc-) or lacto-N-

69 ansferases and fucosyltransferases recognize N-acetyllactosamine in a different conformation.

70 a for 4-6 showed that each enzyme recognizes N-acetyllactosamine in a low minimum energy conformation

71 T-3 plays a critical role in 3'-sulfation of N-acetyllactosamine in both O- and N-glycans.

72 ransferase, was capable of synthesizing poly-N-acetyllactosamine in core 2 branched oligosaccharides.

73 demonstrate the importance of Gal-1-binding N-acetyllactosamines in controlling the fate and functio

74 consistent with previous findings that poly-N-acetyllactosamines in human erythrocytes, PA-1 embryon

75 Poly-N-acetyllactosamines in mucin-type O-glycans can be form

76 the present study, we first found that poly-N-acetyllactosamines in N-glycans are most efficiently s

77 e presence of core 1 O-glycans, but not poly-N-acetyllactosamine, in apically targeted MUC1 and chime

78 I-branched poly-N-acetyllactosamine is a unique carbohydrate composed of

79 Poly-N-acetyllactosamine is a unique carbohydrate composed of

80 Poly-N-acetyllactosamine is a unique carbohydrate that can ca

81 It has been shown that the amount of poly-N-acetyllactosamine is increased in N-glycans, when they

82 N-acetyllactosamine is the most prevalent disaccharide m

83 enous lectin that recognizes glycans bearing N-acetyllactosamine (LacNAc) epitopes, induces branching

84 ces (Galbeta1-4GlcNAc)(n) when compared with N-acetyllactosamine (LacNAc) glycans (Galbeta1-4GlcNAc).

85 Galectins bind N-acetyllactosamine (LacNAc) units within N-glycans init

86 lycan that has N-acetylglucosamine (GlcNAc), N-acetyllactosamine (LacNAc), and unnatural Galalpha(1,4

87 anti-skin inflammatory activity by ablating N-acetyllactosamine (LacNAc), sialyl Lewis X (sLe(X)), a

88 re that sialylated glycosphingolipids with 5 N-acetyllactosamine (LacNAc, Galbeta1-4GlcNAcbeta1-3) re

89 bilized extended glycans containing terminal N-acetyllactosamine (LN; Galbeta1-4GlcNAc) sequences on

90 est that metabolic lowering of Gal-1-binding N-acetyllactosamines may attenuate tumor growth by boost

91 zyme is responsible for the synthesis of the N-acetyllactosamine moiety.

92 h transfers a galactose molecule to terminal N-acetyllactosamine (N-lac) present on various glycoprot

93 terminate in N-acetyllactosamine and sialyl-N-acetyllactosamine, Neu5Ac alpha 2-->3Gal beta 1-->4Glc

94 Poly-N-acetyllactosamine oligomer is a type-2 glycan core fro

95 Development of an effective synthesis of N-acetyllactosamine oligomers will therefore provide a n

96 he programmable one-pot synthesis of various N-acetyllactosamine oligomers.

97 obtained for N-acetyllactosamine and sialyl-N-acetyllactosamine oligosaccharide antennae from biante

98 MECA-79 antibody, which reacts with 6-sulfo N-acetyllactosamine on extended core 1 O-glycans.

99 ine (LN; Galbeta1-4GlcNAc) sequences on poly-N-acetyllactosamine (PL; (-3Galbeta1-4GlcNAcbeta1-)(n))

100 n olfactory sensory neurons (OSNs) with poly-N-acetyllactosamine (PLN) oligosaccharides determined by

101 hibited higher binding for glycans with poly-N-acetyllactosamine (poly(LacNAc)) sequences (Galbeta1-4

102 Enzymatic reduction in surface poly-N-acetyllactosamine (polyLacNAc) glycans in HL60 cells r

103 ibody (MAb) 3F11, a MAb which recognizes the N-acetyllactosamine portion of strain 35000HP LOS.

104 A77 lacks the galactose residue found in the N-acetyllactosamine portion of the strain 35000HP LOS as

105 ant lacks the galactose residue found in the N-acetyllactosamine portion of the strain 35000HP LOS.

106 e, termed Gal3ST-3, that acts exclusively on N-acetyllactosamine present in N-glycans and core2-branc

107 eisseria gonorrhoeae sialylates the terminal N-acetyllactosamine present on its lipooligosaccharide (

108 g moderate amounts of sialyl Lewis X in poly-N-acetyllactosamines produced large numbers of lung tumo

109 abundance of the Lewis(x) sequence based on N-acetyllactosamine recognized by anti-L5, and a paucity

110 ucity of the Lewis(x) sequence based on poly-N-acetyllactosamine recognized by anti-SSEA-1; (ii) insi

111 N-acetylglucosamine residues within the poly(N-acetyllactosamine) repeat sequence and signals represe

112 OS glycoforms containing di-, tri-, and poly-N-acetyllactosamine repeats added to the terminal region

113 osamine is a unique carbohydrate composed of N-acetyllactosamine repeats and provides the backbone st

114 branched oligosaccharides with multiple poly-N-acetyllactosamine repeats is nearly abolished by AZT c

115 -TI leads to efficient and equal addition of N-acetyllactosamine repeats on both side chains of GlcNA

116 Starting with this preformed acceptor, N-acetyllactosamine repeats were added almost equally to

117 First, N-acetyllactosamine repeats were more readily added to t

118 dramatically as the acceptors contained more N-acetyllactosamine repeats, consistent with the fact th

119 n acceptors containing increasing numbers of N-acetyllactosamine repeats, in contrast to beta4Gal-TI,

120 uestion of how the gonococcus infects men if N-acetyllactosamine residues are substituted by Neu5Ac d

121 N-acetyllactosamine residues on LOS must be free of N-ac

122 The structure of BT1043 complexed with N-acetyllactosamine reveals that recognition is mediated

123 , the transfected cells showed a decrease in N-acetyllactosamine sialylation.

124 amine extension mostly along the linear poly-N-acetyllactosamine side chain.

125 them, cores 2 and 4 are important for having N-acetyllactosamine side chains, which can be further mo

126 3Gal-3, -4, and -6, which act on the type II N-Acetyllactosamine structure (Galbeta1,4GlcNAc) to crea

127 expressed enzyme that synthesizes the beta4-N-acetyllactosamine structure in glycoconjugates.

128 Galectin-3 binds poly-N-acetyllactosamine structures on glycoproteins, but its

129 they produced extended GlcNAc-sulfated poly-N-acetyllactosamine structures with more than four repea

130 onger carbohydrate substrates that have poly-N-acetyllactosamine structures, suggesting the involveme

131 te that beta4Gal-TIV is responsible for poly-N-acetyllactosamine synthesis in core 2 branched O-glyca

132 results, taken together, indicate that poly-N-acetyllactosamine synthesis in N-glycans and core 2- a

133 l-TI was found to be most efficient for poly-N-acetyllactosamine synthesis in N-glycans.

134 h is a rate-limiting step in I-branched poly-N-acetyllactosamine synthesis, allowing poly-N-acetyllac

135 1, an enzyme proposed to be involved in poly-N-acetyllactosamine synthesis, were causal for congenita

136 termine how this increased synthesis of poly-N-acetyllactosamines takes place, the branched acceptor

137 multiple internal GlcNAc of unbranched poly-N-acetyllactosamine, termed "myeloglycan," the physiolog

138 hed O-glycans contain fewer and shorter poly-N-acetyllactosamines than N-glycans in many cells.

139 ing activity of the B. arenarum galectin for N-acetyllactosamine, the human blood group A tetrasaccha

140 finities and -delta H values for lactose and N-acetyllactosamine, the soybean agglutinin possesses si

141 possess essentially the same affinities for N-acetyllactosamine, the two mutants possess much lower

142 ltransferase and beta4Gal-TI efficiently add N-acetyllactosamine to linear poly-N-acetyllactosamines.

143 accharide (LOS) containing a terminal sialyl N-acetyllactosamine trisaccharide.

144 ng upon common 3'-sialylated and/or sulfated N-acetyllactosamine-type precursors.

145 ore than four repeats of the GlcNAc-sulfated N-acetyllactosamine unit in the presence of corneal N-ac

146 , the Lc3 synthase could extend the terminal N-acetyllactosamine unit of nLc4 and also had a broad sp

147 core with > 10 monosaccharide units (or > 4 N-acetyllactosamine units) showed E-selectin binding und

148 e having at least 10 monosaccharide units (4 N-acetyllactosamine units) with internal multiple fucosy

149 class Ib molecules studied to date, carries N-acetyllactosamine units.

150 Ic, and the large difference in the price of N-acetyllactosamine vs. lactose, it is suggested that la

151 The efficacy of the galectin-3 inhibitor N-acetyllactosamine was evaluated in TGR(mREN2)27 (REN2)

152 ucosaminyltransferase, the formation of poly-N-acetyllactosamine was found to be extremely inefficien

153 When a beta1,6-GlcNAc branched poly-N-acetyllactosamine was incubated with a mixture of beta

154 Surprisingly, poly-N-acetyllactosamine was more efficiently formed on Galbe

155 ng when galectin-3, with preference for poly-N-acetyllactosamine, was depleted from polarized MDCK ce

156 tivity and both activities were inhibited by N-acetyllactosamine, whereas a C-terminal deletion mutan

157 lactosamine branches attached to linear poly-N-acetyllactosamine, which is synthesized by I-branching

158 ly to beta1,6-GlcNAc attached to linear poly-N-acetyllactosamines, while beta1, 3-N-acetylglucosaminy

159 librium dialysis, N-Gal-1 and V5D-Gal-1 bind N-acetyllactosamine with a Kd approximately 90 microM, w

160 Thus, these data imply that capping N-acetyllactosamine with alphaGal or alphaFuc and the co

161 of the terminal alpha-Gal or whether capping N-acetyllactosamine with another oligosaccharide would a